# Jane Street Group LLC

Type: Company

Source: GetYourBrief — https://getyourbrief.com/entity/jane-street-group-llc
Canonical HTML page: https://getyourbrief.com/entity/jane-street-group-llc

## Timeline

- **2026-08-14**: STE trading level — STERIS shares opened at $232.88, within a 52-week range of $195.14 to $269.44.
- **2026-08-13**: Q2 earnings released; EPS beats consensus — Company reported ($1.40) EPS versus ($1.55) consensus; shares rose $0.05 to $0.57 on 2.3x average volume
- **2026-07-17**: Weiss Ratings reiterates Sell — Restated a 'sell (e+)' rating on MBRX shares in a research note
- **2026-06-02**: Director Breeden insider sale — STERIS director Richard C. Breeden sold 1,481 shares at an average price of $209.51, totaling $310,284.31 — a 3.66% reduction leaving 38,964 shares directly owned.
- **2026-06**: Q2 2026 new positions — Stoneridge Investment Partners initiated a new 4,497-share stake valued at $1,027,000. Elevation Wealth Partners raised its stake 1,130% to 123 shares ($26,000).
- **2026-05-16**: Wall Street Zen downgrades MBRX — Cut its rating from 'sell' to 'strong sell' in a research note
- **2026-03**: Q1 2026 institutional accumulation — Goldman Sachs lifted its position 32.3% to 242,732 shares ($55.0M). Jane Street increased 38.9% to 20,716 shares ($4.7M). Woodline Partners grew 40.0% to 8,300 shares ($1.88M). Jones Financial raised 46.1%. Empowered Funds added 16.1%. Geneos Wealth grew 416.0%. Western Wealth opened a new $25,000 stake.
- **2025-12**: Jane Street Group discloses new MBRX position — Acquired 22,550 shares valued at approximately $75,000 during Q4 2025, per SEC filing, representing about 1.11% of the company
- **2025-12**: Q4 2025 13F filings — Activest Wealth Management raised its STERIS stake 423.8% to 110 shares ($28,000), and Measured Wealth Private Client Group opened a new position valued at about $28,000.

## Recent coverage (8 stories, network-wide)

### STERIS Institutional Ownership Hits 94.69% on 32.3% Goldman Boost
2026-08-17 02:11:21 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2

A wave of institutional accumulation in STERIS plc — including a 32.3% Goldman Sachs position increase and a new $1.03 million Stoneridge stake in Q2 2026 — signals confidence in the medical equipment provider's infection-prevention franchise. With institutions now holding 94.69% of shares and the company maintaining a 0.23 debt-to-equity ratio, STERIS appears positioned to absorb hospital capital-expenditure cycles. A modest June insider sale by director Richard C. Breeden at $209.51 is a minor contrarian signal in an otherwise bullish institutional pattern.
Full story: https://gethealthbrief.com/story/steris-institutional-ownership-infection-prevention-demand

### Goldman Sachs Ups STERIS 32.3% as Institutions Own 94.69%
2026-08-17 02:11:06 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

STERIS plc's latest 13F disclosures show a broad institutional accumulation wave: Goldman Sachs raised its stake 32.3% to 242,732 shares ($55M) in Q1, and Stoneridge Investment Partners opened a new $1.03M position in Q2. With 94.69% of the float owned by institutions and a director selling $310K of stock in June, the signals are mixed. Conservative leverage (debt-to-equity 0.23) and a 1.35 quick ratio support the long case.
Full story: https://getfinancebrief.com/story/steris-13f-accumulation-goldman-institutional-ownership

### MBRX Down 97% to $0.57 Despite EPS Beat: $22 Target Stale?
2026-08-17 00:56:51 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Moleculin Biotech shares rose 9.6% to $0.57 after a narrower-than-expected Q2 loss, yet the stock remains down roughly 97% from its 12-month high, with analysts' average $22.00 target detached from reality. The real signal for traders is a 2.3x volume surge, a beta of 1.83, and thin 15.52% institutional ownership.
Full story: https://getfinancebrief.com/story/mbrx-down-97-percent-eps-beat-22-target-stale

### Moleculin's $4.06M Market Cap vs ($1.40) EPS: Pipeline Survival?
2026-08-17 00:56:41 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Clinical-stage Moleculin Biotech is now valued at just $4.06 million after a 97% collapse from its 52-week high, raising existential questions about its ability to fund development of therapies for resistant tumors and viral infections. The EPS 'beat' of ($1.40) versus ($1.55) is a paper figure — no revenue, cash balance, or clinical milestone accompanied the report.
Full story: https://getbiobrief.com/story/moleculin-4m-market-cap-eps-loss-pipeline-survival

### Smith-Midland Posts $0.26 EPS, $23.36M Revenue; Shares Rise 1.7%
2026-08-15 00:41:18 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Smith-Midland's latest quarterly results show a profitable small-cap with an almost 20% return on equity and very low leverage, even as the stock trades about 35% below its 52-week high. The $0.26 EPS and $23.36 million revenue figure, combined with rising institutional holdings, make it a watch item for value-oriented small-cap investors. However, the stock remains below its 50-day and 200-day moving averages, keeping the technical picture cautious.
Full story: https://getfinancebrief.com/story/smith-midland-q2-2026-earnings-finance

### ENSC Shorts Up 619.9% at $0.30; FCUV Revenue $0.05M
2026-08-13 01:23:24 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Ensysce Biosciences short interest soared 619.9% to 364,278 shares as its stock trades at $0.30, while Focus Universal posted just $0.05M in quarterly revenue. The data highlights severe financial fragility across two small healthcare and device innovators.
Full story: https://gethealthbrief.com/story/ensc-shorts-up-619-9-fcuv-revenue-0-05m

### SCYX Short Interest Plunges 87.6% as ENSC Spikes 619.9%
2026-08-13 01:23:11 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

SCYNEXIS shorts collapsed 87.6% to 320,181 shares, signaling bear exhaustion, while Ensysce Biosciences short interest exploded 619.9% to 364,278. Focus Universal also saw a 282.8% build, reflecting a stark divergence in microcap biotech sentiment.
Full story: https://getbiobrief.com/story/scyx-short-interest-plunges-87-6-ensc-spikes-619-9

### Retail Partner Cardlytics Sees CEO Sell $70K as Stock Tanks 87% to $4.37
2026-08-12 11:34:01 · Sector: retail · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Cardlytics, whose platform powers cashback offers inside banking apps for major retailers, is under financial strain—its stock has plummeted to $4.37 and the CEO has unloaded shares. The company’s tiny $25M market cap and negative earnings put its future in doubt, directly affecting retail brands that depend on it for consumer acquisition and loyalty campaigns.
Full story: https://getretailbrief.com/story/cardlytics-insider-selling-retail-partner-risk

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.